76 related articles for article (PubMed ID: 13129395)
21. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
22. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
McQuade P; Knight LC; Welch MJ
Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
[TBL] [Abstract][Full Text] [Related]
24. Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature.
Muzykantov VR; Barnathan ES; Atochina EN; Kuo A; Danilov SM; Fisher AB
J Pharmacol Exp Ther; 1996 Nov; 279(2):1026-34. PubMed ID: 8930213
[TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
27. On-demand cleavable linkers for radioimmunotherapy.
Kumaresan PR; Luo J; Lam KS
Methods Mol Biol; 2009; 539():191-211. PubMed ID: 19377973
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
29. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
31. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
32. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
[TBL] [Abstract][Full Text] [Related]
33. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
34. Targeting endothelial growth with monoclonal antibodies against Tie-1 kinase in mouse models.
Karnani P; Kairemo K
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3821S-6S. PubMed ID: 14506178
[TBL] [Abstract][Full Text] [Related]
35. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
36. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
[TBL] [Abstract][Full Text] [Related]
38. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
39. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
40. The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs.
Ravn P; Stahn R; Danielczyk A; Faulstich D; Karsten U; Goletz S
Cancer Immunol Immunother; 2007 Sep; 56(9):1345-57. PubMed ID: 17310382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
